Karolinska Development (Sweden) Buy or Sell Recommendation

Macroaxis provides Karolinska Development AB buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Karolinska Development positions. The advice algorithm takes into account all of Karolinska Development AB available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Karolinska Development buy-and-hold prospective. Please see also Karolinska Development Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus

Investment Horizon


Risk Tolerance

Execute Advice
Karolinska Development AB -- Sweden Stock  

SEK 6.3  0.15  2.33%

Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding Karolinska Development AB is 'Hold'.
For the selected time horizon Karolinska Development AB has a risk adjusted performance of (0.036366), jensen alpha of (0.51), total risk alpha of (1.99), sortino ratio of 0.0 and treynor ratio of (0.57)
We provide buy, hold, or sell recommendation to complement the last-minute expert consensus on Karolinska Development AB. Our dynamic recommendation engine harnesses multi - dimensional algorithm to analyze the entity potential to grow using all technical and fundamental data available at the time. To make sure Karolinska Development AB is not overpriced, please verify all Karolinska Development AB fundamentals including its EBITDA, Cash and Equivalents and the relationship between Gross Profit and Net Income .

Returns Distribution Density

Mean Return0.37Value At Risk4.41
Potential Upside7.34Standard Deviation4.04
 Return Density 

Karolinska Development Greeks

Alpha over DOW
βBeta against DOW=0.67
Overall volatility
 IrInformation ratio =0.14

Karolinska Development Volatility Alert

Karolinska Development AB exhibits very low volatility with skewness of 1.09 and kurtosis of 0.66. However, we advise investors to further study Karolinska Development AB technical indicators to make sure all market info is available and is reliable.
 Better Than Average     
 Worse Than Average Compare Karolinska Development to competition
FundamentalsKarolinska DevelopmentPeer Average
Return On Equity(156.17) % (15.17) %
Return On Asset(4.21) % (15.64) %
Operating Margin(547.1) % (10.91) %
Current Valuation677.96 M152.14 B
Shares Outstanding62.61 M1.43 B
Price to Earning(5.07) times40.69 times
Price to Book9.33 times14.44 times
Price to Sales72.3 times17.81 times
Revenue5.32 M9.85 B
Gross Profit5 M21.75 B
EBITDA(29.06 M)1.41 B
Net Income(87.33 M)517.71 M
Cash and Equivalents189.13 M3.89 B
Cash per Share2.95 times5.17 times
Total Debt357.55 M7.36 B
Debt to Equity868.2 % 0.72 %
Current Ratio25.5 times3.3 times
Book Value Per Share0.64 times13.64 times
Cash Flow from Operations3.41 M1.25 B
Earnings Per Share(1.57) times2.3 times
Number of Employees1310.67 K
Market Capitalization384.7 M29.78 B
Total Asset449 M126.86 B
Retained Earnings(1.85 B)38.24 B
Working Capital250 M3.58 B
Current Asset259 M36.8 B
Current Liabilities9 M33.34 B
Z Score-5.0708.73


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Currently Unavailable

Piotroski F Score

Currently Unavailable

Financial Leverage

Risk Adjusted Performance(0.036366)
Market Risk Adjusted Performance(0.56)
Mean Deviation3.1
Coefficient Of Variation(1,096)
Standard Deviation4.04
Information Ratio(0.14)
Jensen Alpha(0.51)
Total Risk Alpha(1.99)
Treynor Ratio(0.57)
Maximum Drawdown14.09
Value At Risk(4.41)
Potential Upside7.34

Current Valuation

Karolinska Development Current Valuation Analysis
Karolinska Development AB is considered the number one company in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Pharmaceuticals And Biosciences industry is now estimated at about 31.55 Billion. Karolinska Development holds roughly 677.96 Million in current valuation claiming about 2.15% of equities listed under Pharmaceuticals And Biosciences industry.